Gadobenate Dimeglumine Injection and Gadopentetate Dimeglumine Injections Proposed for Selection in Xinjiang Uygur Autonomous Region's 26-Province Alliance Centralized Volume-Based Procurement

Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the centralized volume-based procurement work of pharmaceuticals for the 26-province alliance in the Xinjiang Uygur Autonomous Region. According to the "Public Announcement of the Comprehensive Review of the Proposed Selected Results for the 26-Province Alliance Centralized Volume-Based Procurement" released by the Xinjiang Uygur Autonomous Region Medical Security Bureau, the company's Gadobenate Dimeglumine Injection and Gadopentetate Dimeglumine Injection are proposed to be selected for this centralized procurement.

Basic Information of the Proposed Selected Products

Impact on the Company

One of the proposed selected products, Gadopentetate Dimeglumine Injection, has been a key source of revenue and performance for the company since its launch in 1992 as the first gadolinium-based contrast agent. The other proposed selected product, Gadobenate Dimeglumine Injection, passed the consistency evaluation in 2024, but to date, it has seen minimal sales.

This centralized procurement is organized by the Xinjiang Uygur Autonomous Region, leading the 26-province (city, autonomous region) alliance. During the procurement cycle, medical institutions will prioritize using the selected drugs from this centralized procurement and ensure the completion of the agreed-upon purchase volume. With these two products now confirmed as selected, and with procurement contracts signed and implemented, this will help increase the market share of the company's gadolinium-based contrast agents and enhance the company's brand influence.